Home › Uterine Cancer › Virginia › Arlington
Uterine Cancer clinical trials in Arlington, VA
3 studies for Uterine Cancer are looking for participants at sites in and around Arlington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, Fairfax · 11 mi away
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- USOR Virginia Cancer Specialists, Fairfax · 11 mi away
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
- Research Site, Falls Church · 4 mi away
- Research Site, Fairfax · 11 mi away
About Uterine Cancer
Uterine cancer is a cancer that forms in tissues of the uterus. It is more likely to happen after menopause. There are things you can do that may help lower your risk.
More about Uterine Cancer on MedlinePlus
Uterine Cancer trials in other cities
- Houston, TX8 studies
- New York City, NY6 studies
- Columbus, OH6 studies
- Boston, MA5 studies
- Philadelphia, PA5 studies
- Miami, FL5 studies
- Austin, TX5 studies
- Pittsburgh, PA4 studies
- Orlando, FL4 studies
- West Palm Beach, FL4 studies
- Chicago, IL4 studies
- Providence, RI4 studies
Other studies in Arlington
- Non-Small Cell Lung Cancer104 studies
- Metastatic Cancer53 studies
- Colorectal Cancer52 studies
- Cancer (all types)48 studies
- Breast Cancer47 studies
- Ovarian Cancer46 studies
- Lung Cancer41 studies
- Endometrial Cancer39 studies
- Pancreatic Cancer33 studies
- Head and Neck Squamous Cell Carcinoma26 studies
- Small Cell Lung Cancer23 studies
- Stomach Cancer20 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.